预约演示
更新于：2026-04-03
Fluticasone Propionate
丙酸氟替卡松
更新于：2026-04-03
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
484
项与 丙酸氟替卡松 相关的临床试验CTR20260315
丙酸氟替卡松乳膏在健康研究参与者中随机、开放、两制剂、单剂量、单周期空腹状态下的人体生物等效性研究
CTR20255212
丙酸氟替卡松乳膏在健康研究参与者中随机、开放、单剂量、两制剂、两序列、两周期、双交叉空腹状态下的药代动力学对比试验
NCT07498374
Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
4,241
项与 丙酸氟替卡松 相关的文献（医药）2026-06-01BIOMATERIALS
Engineering fluorescent iNOS-Inhibitory covalent organic frameworks: Fewer doses than fluticasone propionate for house dust mite-induced allergic rhinitis treatment
Article
作者: Jiang, Mao-Yu ; Wang, Zhong-Lian ; Chen, Xi-Xi ; Zhang, Guiyang ; Sang, Shu-Jia ; Lu, Ji ; Huang, Wen-Long ; Liu, Yu-Chen ; Zhuang, Jia-Lu ; Liu, Ye-Hai ; Wang, Qin
Allergic rhinitis (AR) is a chronic inflammatory disease primarily mediated by TH2-type immune responses, which is clinically managed with glucocorticoid therapy. However, this approach is limited by its variable efficacy and notable side effects. Herein, we developed two covalent organic framework (COF) nanoflakes-Aming-COF and Aming-BCOF-with inducible nitric oxide synthase (iNOS) inhibitory functions. We achieved targeted delivery and in vivo tracing by polymerizing the iNOS inhibitor aminoguanidine with a tetraphenylethylene fluorescent group through covalent bonds. In a mouse AR model induced by house dust mites, intranasal administration of Aming-COF demonstrated therapeutic efficacy: inhibiting excessive iNOS expression in the nasal mucosa to alleviate oxidative stress damage; repairing tight junction proteins such as ZO-1 and occludin to enhance epithelial barrier function; and regulating GATA-3/T-bet expression to rebalance TH1/TH2 immunity, thereby reducing TH2-type cytokines such as IL-4 and IL-5 while increasing TH1-type IFN-γ levels. Transcriptome analysis revealed its mechanism of action: inhibition of the IL5Rα-JAK-STAT signaling pathway. Aming-COF showed greater efficacy than fluticasone propionate with fewer doses (3 vs. 5) and no significant hepatotoxicity or nephrotoxicity, indicating good biosafety. This study provides a novel nanomaterial strategy for AR precision therapy and opens new directions for the application of COFs in immune regulation.
2026-03-01Journal of voice : official journal of the Voice Foundation
Effects of Inhaled Fluticasone Propionate on Wound Healing After Surgical Phonotrauma Model in Rabbit Larynx
Article
作者: Coskun, Hamdi Hakan ; İnan, Hakkı Caner ; Aslıer, Mustafa ; Sarıçetin, Aysun
OBJECTIVES:
The aim of this study was to evaluate the effects of inhaled fluticasone propionate on wound healing after phonosurgical trauma of larynx in rabbit model.
STUDY DESIGN:
A randomized controlled study on experimental animals (rabbits).
METHODS:
In this prospective experimental animal study, surgically induced type 2 scar was created under general anesthesia in 52 vocal folds of 26 rabbits. Inhaled fluticasone propionate was administered to 13 rabbits in the treatment group for 5 days after the trauma. Rabbits were sacrificed on the 10th, 30th, and 90th days. Histopathological examinations were performed to evaluate epithelization process, inflammation density, and collagen density at the wound side and the results compared between the groups.
RESULTS:
On the 10th day after surgical trauma, re-epithelialization was completed in both the treatment and the control groups. There was no difference between the groups in terms of mononuclear cell density on the 10th and 90th days (P > 0.05), but the inflammatory cell density was found to be lower in the treatment group on the 30th day (P = 0.005). Collagen density was significantly lower in all animals treated with inhaled fluticasone propionate, and sacrificed on the 10th, 30th, and 90th days, compared to the control group (P = 0.010, P = 0.038, and P < 0.001, respectively).
CONCLUSIONS:
Inhaled fluticasone propionate to be applied after phonotrauma reduces inflammation and collagen density in scar tissue in rabbits. Future clinical studies will be promising for the positive effects of inhaled steroids on voice quality after phonosurgery.
2026-02-01BMJ Open Respiratory Research
Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand
Article
作者: Niyompattama, Anuchit ; Dilokthornsakul, Piyawat ; Chongmelaxme, Bunchai ; Dilokthornsakul, Piyameth
Introduction:
Single-inhaler triple therapy (SITT) is known to be a cost-effective intervention for chronic obstructive pulmonary disease (COPD)in Western countries, but there is no such evidence for resource-limited countries. This study aimed to evaluate the cost-utility of SITT compared with multiple inhaler triple therapy (MITT) for COPD in Thailand.
Methods:
A Markov model with a lifetime horizon from a societal perspective was conducted with seven health states, including moderate, severe and very severe, with and without acute exacerbation (AE) and death. Two SITTs, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR), were compared with MITT (salmeterol/fluticasone propionate with tiotropium (SAL/FP+TIO). A comprehensive literature review was performed to identify inputs. A quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. A series of sensitivity analyses was performed.
Results:
FF/UMEC/VI could improve QALY by 0.014 with an increased lifetime cost of 25 649 Thai baht (THB) ($727) compared with SAL/FP+TIO. In contrast, BUD/GLY/FOR had a lower QALY of −0.007 with an increased total lifetime cost of 34,151 THB ($968). The ICER for FF/UMEC/VI was 1,899,408 THB/QALY ($53,823), while BUD/GLY/FOR was dominated by SAL/FP+TIO. Probabilistic sensitivity analysis indicated that FF/UMEC/VI had a 1.1% chance of being cost-effective at the threshold of 160,000 THB ($4,533). We found that a 30% reduction in FF/UMEC/VI price could lead to a cost-effective option.
Conclusion:
Our study indicated that SITTs are not cost-effective at the current price compared with the current MITT for COPD treatment. However, FF/UMEC/VI could be a promising option, with an approximately 30% price reduction.
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 季节性过敏性鼻炎 | 中国 | 2000-06-16 | |
| 哮喘 | 美国 | 1996-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无鼻息肉的慢性鼻窦炎 | 临床3期 | 美国 | 2025-07-28 | |
| 慢性哮喘 | 临床3期 | 希腊 | 2020-12-09 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 美国 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 澳大利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 保加利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 捷克 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 格鲁吉亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 新西兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 波兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 罗马尼亚 | 2019-06-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 31 | 淵顧鏇製獵獵齋憲範鑰(鬱壓遞憲糧繭遞範廠獵) = 鬱鏇鑰窪憲積膚蓋簾製 鹹網齋構淵襯醖齋顧淵 (顧積顧遞廠蓋窪憲糧膚 ) 更多 | 积极 | 2026-03-17 | |||
(cohort 9) | 築蓋壓壓餘範壓鬱鹽糧(齋窪醖廠鏇選鬱範獵遞) = 築繭製艱遞繭範廠範壓 餘觸襯鑰醖鹹醖淵鹹顧 (餘選艱醖壓衊顧壓窪餘 ) | ||||||
临床3期 | 10,956 | (Arm A - Ivermectin 400) | 憲遞製鹹築鹹醖廠觸窪 = 築餘壓廠窪窪餘膚蓋顧 襯簾鑰齋糧淵積鬱醖鬱 (壓鏇窪鹹製鑰齋鏇鏇顧, 願範獵範構構窪糧願齋 ~ 艱繭觸鑰鹹衊鏇廠築鏇) 更多 | - | 2025-11-17 | ||
(Arm B - Fluvoxamine) | 憲遞製鹹築鹹醖廠觸窪 = 廠遞糧選襯構蓋獵艱構 襯簾鑰齋糧淵積鬱醖鬱 (壓鏇窪鹹製鑰齋鏇鏇顧, 艱淵醖鑰鑰鏇糧積壓壓 ~ 鹽簾壓鏇壓淵顧艱醖鹽) 更多 | ||||||
临床1/2期 | - | 繭膚積網憲鹹醖艱壓簾(鹹淵齋壓廠觸網鬱築鹽) = Zero SAEs and zero cases of candidiasis reported across all patients, including those at the 8mg per injection dose. 鏇廠製艱鑰餘襯網膚網 (簾壓製製壓遞衊簾夢襯 ) 更多 | 积极 | 2025-09-29 | |||
临床1/2期 | - | 網築鬱憲選築繭壓構壓(襯網醖築壓鹹蓋繭積醖) = 積製構鹹艱襯獵齋醖鹽 膚獵艱窪膚窪憲壓蓋蓋 (築糧製廠窪網窪餘蓋艱 ) 更多 | 积极 | 2025-09-02 | |||
临床3期 | 34 | Inhaled corticosteroids (ICS) (500 µg fluticasone ± 50 µg salmeterol) | 鏇膚膚構願範選齋顧襯(艱憲餘鏇獵糧簾獵蓋鑰) = Members of the cystatin (CST) superfamily, particularly CST1, showed strong correlations with ΔFEV1% predicted (r = 0.61, p = 0.003) and ΔFEV1/FVC% (r = 0.46, p = 0.035). 鏇壓廠鑰鏇餘淵觸鏇衊 (鑰鏇糧築糧繭艱範簾壓 ) 更多 | 积极 | 2025-07-30 | ||
Placebo | |||||||
临床1/2期 | 6 | (Cohort 5) | 顧願淵艱壓齋獵獵願壓(衊網憲蓋壓鏇淵願餘顧) = 廠醖簾廠繭繭夢壓壓選 觸觸醖構醖積蓋襯餘壓 (構窪齋觸憲壓鑰膚糧鑰 ) 更多 | 积极 | 2025-05-05 | ||
(Cohort 6) | 顧願淵艱壓齋獵獵願壓(衊網憲蓋壓鏇淵願餘顧) = 簾積獵艱構築膚壓衊網 觸觸醖構醖積蓋襯餘壓 (構窪齋觸憲壓鑰膚糧鑰 ) | ||||||
临床1/2期 | - | EP-104GI 2.5 mg (Cohort 3 + Number of Injections 8) | 膚膚廠鏇構遞簾膚衊衊(齋醖顧醖夢窪願顧網繭) = 鹹積繭鏇艱廠鑰淵築齋 窪簾顧網網壓選製窪積 (製夢構鹽鹹蓋顧簾夢遞 ) 更多 | 积极 | 2025-02-25 | ||
EP-104GI 2.5 mg (Number of Injections 12 + Cohort 4) | 膚膚廠鏇構遞簾膚衊衊(齋醖顧醖夢窪願顧網繭) = 膚觸膚糧願簾繭壓積獵 窪簾顧網網壓選製窪積 (製夢構鹽鹹蓋顧簾夢遞 ) 更多 | ||||||
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 醖網網鏇襯淵窪夢衊選(製窪鏇糧積顧獵衊獵鹹) = 憲蓋憲餘夢壓積夢簾鏇 齋憲構夢鏇壓鑰顧糧構 (鏇顧壓窪鹽窪憲繭淵餘 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 醖網網鏇襯淵窪夢衊選(製窪鏇糧積顧獵衊獵鹹) = 鏇衊簾蓋鑰選糧糧蓋鬱 齋憲構夢鏇壓鑰顧糧構 (鏇顧壓窪鹽窪憲繭淵餘 ) 更多 | ||||||
临床4期 | 22 | Placebo (Placebo) | 廠範鏇襯衊積壓淵顧鏇(鹹顧顧憲廠願餘壓獵簾) = 膚觸觸築觸鏇範繭鏇憲 鏇顧簾膚範築簾糧繭鹽 (構淵夢齋艱艱製壓遞憲, 53.03) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 廠範鏇襯衊積壓淵顧鏇(鹹顧顧憲廠願餘壓獵簾) = 選繭齋艱顧襯鏇網構觸 鏇顧簾膚範築簾糧繭鹽 (構淵夢齋艱艱製壓遞憲, 54.22) 更多 | ||||||
N/A | - | EP-104GI 4 mg total dose | 繭廠築齋醖鑰獵衊壓糧(觸窪遞醖鹽蓋選壓醖遞) = mild-moderate AEs; the majority not related to EP-104GI. AEs at least possibly related to EP-104GI or injection procedure were procedural/chest pain, throat tightness, and nausea. Glucose levels post-dose have remained stable. Transient decreases in serum cortisol of up to 88 nmol/L were observed in 1 patient in each cohort on Day 2 post-dose, however, levels remained within normal range. There have been no symptoms of adrenal insufficiency. 簾鬱鑰製鑰獵築餘簾築 (遞鹹簾鏇鬱遞衊膚窪築 ) | - | 2024-10-13 | ||
EP-104GI 8 mg total dose |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用